

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WAI YUEN TONG MEDICINE HOLDINGS LIMITED

(位元堂藥業控股有限公司*)

(Incorporated in Bermuda with limited liability)

(Stock Code: 897)

POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 30 JANUARY 2024

The Board is pleased to announce that the proposed ordinary resolution set out in the SGM Notice in respect of the Revolving Loan Facility Agreement was duly passed by the Independent Shareholders at the SGM held on 30 January 2024 by way of a poll.

References are made to (a) the announcement dated 18 December 2023 issued by Wai Yuen Tong Medicine Holdings Limited (the “**Company**”); and (b) the circular of the Company dated 11 January 2024 (the “**Circular**”) containing the notice dated 11 January 2024 (the “**SGM Notice**”) convening the special general meeting (the “**SGM**”) held on 30 January 2024. Capitalised terms used herein shall have the same meanings as defined in the Circular unless otherwise defined.

POLL RESULTS OF THE SGM

The Board is pleased to announce that the proposed ordinary resolution set out in the SGM Notice in respect of the Revolving Loan Facility Agreement was duly passed by the Independent Shareholders at the SGM held on 30 January 2024 by way of a poll and the poll results are as follows:

Ordinary resolution set forth in the SGM Notice		Number of Shares (Approximate %)		Total number of Shares voted (%)
		For	Against	
1.	<p>(a) To approve, confirm and ratify the revolving loan facility agreement dated 18 December 2023 entered into between Wang On Group Limited (“WOG”) and Wai Yuen Tong Medicine Company Limited (the “Revolving Loan Facility Agreement”) and the transactions contemplated thereunder and the implementation thereof; and</p> <p>(b) to authorise any one director of the Company (the “Director(s)”) to do all such acts and things as the Director in his/her sole and absolute discretion deems necessary, desirable or expedient to implement, give effect to and/or complete the Revolving Loan Facility Agreement and the transactions contemplated thereunder.[#]</p>	38,625,000 (99.99%)	3,279 (0.01%)	38,628,279 (100%)

[#]Note: The full text of the above resolution proposed at the SGM is set out in the SGM Notice.

Tricor Secretaries Limited, the Company’s branch share registrar and transfer office in Hong Kong, was appointed as the scrutineer at the SGM for the purpose of vote-taking.

As at the date of the SGM, the total number of issued Shares was 1,171,102,888. As disclosed in the Circular and as at the date of the SGM, WOG was considered to have a material interest in the Revolving Loan Facility Agreement which was different from other Shareholders; therefore, WOG and its associates were required to abstain from voting on the ordinary resolution no. 1. Rich Time Strategy Limited (a wholly-owned subsidiary of WOG), being an associate of WOG and holding 810,322,940 Shares, representing approximately 69.19% of the total issued Shares, was required to abstain from voting on the ordinary resolution no. 1. The Board confirmed that Rich Time Strategy Limited had abstained from voting in respect of such resolution. Accordingly, the total number of Shares entitling the Shareholders to attend and vote on the ordinary resolution no. 1 was 360,779,948, representing approximately 30.81% of the total issued Shares.

Save as disclosed above and in the Circular, there were no Shares entitling the Shareholders to attend and abstain from voting in favour as set out in Rule 13.40 of the Listing Rules and none of the Shareholders were entitled to attend and vote only against the ordinary resolution at the SGM and there were no parties who have stated their intention in the Circular and the SGM Notice to vote against the above ordinary resolution or to abstain have done so at the SGM. Ms. Law Man Yee, Anita, an executive Director, and Mr. Li Ka Fai, David, an independent non-executive Director, attended the SGM in person.

By Order of the Board
WAI YUEN TONG MEDICINE HOLDINGS LIMITED
(位元堂藥業控股有限公司*)
Tang Wai Man
Executive Director

Hong Kong, 30 January 2024

As at the date of this announcement, the Board comprises Mr. Tang Ching Ho, Ms. Tang Wai Man and Ms. Law Man Yee, Anita as executive Directors, and Mr. Siu Man Ho, Simon, Mr. Li Ka Fai, David, Professor Sit Wing Hang and Professor Chan Wing Kwong as independent non-executive Directors.

** For identification purpose only*